Overview

PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis

Status:
Completed
Trial end date:
2017-08-31
Target enrollment:
Participant gender:
Summary
This is an open label, proof of concept (PoC) study of Cenicriviroc (CVC) in adult participants with Primary Sclerosing Cholangitis (PSC). The main objective of this PoC study is to assess changes in alkaline phosphatase (ALP) both individually and as a group, over 24 weeks of treatment with CVC.
Phase:
Phase 2
Details
Lead Sponsor:
Tobira Therapeutics, Inc.
Treatments:
Cenicriviroc
TAK-652